Given the limited anti-tumor effect observed in 4T1 tumor-bearing mice, we next asked whether combined a-TEA-LS + aPD-L1 therapy exhibited therapeutic efficacy in two additional models, Eph4 1424 tumor-bearing mice, which express constitutively active MEK1 (28), and the PyMT-MMTV Tg model of spontaneously arising mammary carcinoma. This evidence concerns the gene MAP2K1 and breast carcinoma.